Fig. 1

Overall survival and progression-free survival among the study patients. Kaplan–Meier curves for overall survival in the intention-to-treat population are presented (a). Overall survival was significantly increased in the EGFR exon 19 deletion group compared with the exon 21 L858R point mutation group (median, 92 vs. 65 months, P = 0.018). Kaplan–Meier curves for progression-free survival are presented for the progression-free-survival population with the two types of epidermal growth factor receptor (EGFR) mutations (b). The median progression-free survival did not differ significantly between patients with the EGFR exon 19 deletion and those with the L858R point mutation (12 vs 14 months, P = 0.302)